Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is described as a leading global provider of transformative intelligence, with news that reflects its activities across Academia & Government, Intellectual Property and Life Sciences & Healthcare. Company announcements frequently highlight new AI-powered tools, analytical reports and customer adoptions that illustrate how Clarivate combines enriched data, analytics and workflow software.
Recent news includes the launch of the Web of Science Research Assistant, a generative AI-powered tool that helps researchers conduct natural-language searches, perform literature reviews and explore visualizations based on more than 120 years of publication and citation data. Clarivate also reports on studies such as the Pulse of the Library report, which surveys thousands of librarians worldwide about AI adoption, open science and budget pressures, and on the annual Highly Cited Researchers list, which recognizes researchers whose work has had broad influence based on Web of Science data.
In Intellectual Property, Clarivate issues updates on solutions like IPfolio and Derwent Patent Monitor, including customer selections by organizations such as Nissan Motor Co., Ltd. and FUJIFILM Holdings Corporation. These stories emphasize how IP management platforms and AI-enabled patent review tools support more efficient IP operations and collaboration between IP and R&D teams.
Life sciences and healthcare news often centers on Clarivate analyses such as the Drugs to Watch report and Companies to Watch reports, which identify emerging therapies and innovative companies using integrated, AI-enhanced datasets. Visitors to this news page can follow Clarivate’s product launches, research reports, customer case studies and investor-related announcements to understand how the company is applying data and AI across its core markets.
Clarivate has launched the Trademark Watch Analyzer, an AI-enhanced solution aimed at improving trademark protection. Announced at the 2024 International Trademark Association Annual Meeting, this tool integrates global trademark and case law data, in-house IP expertise, and advanced AI technology. The analyzer covers trademark datasets from 258 countries and 191 trademark registers, along with data from over 7 million trademark litigation cases. This system automates key trademark watching tasks and prioritizes result sets, allowing clients to rank results based on success or opposition chances. According to CompuMark data, trademark applications have doubled since 2014, increasing the need for vigilant trademark monitoring. Gordon Samson, Clarivate's President of Intellectual Property, emphasized that this solution helps clients save time, cost, and resources while ensuring global trademark monitoring and automated alerts.
Clarivate released the 2024 Non-Practicing Entity (NPE) Global Litigation Report, detailing NPE enforcement activities and patent challenges globally. The U.S., Germany, and Mainland China lead in NPE litigation cases, with the U.S. accounting for 97.2% from 2018-2023, Germany 1.8%, and China 0.4%. The report notes a 43% decrease in U.S. NPE cases, a 600% increase in China, and a decline in Germany from 2018. The report found that overall NPE infringement actions declined globally from 2012-2019 and stabilized at around 2,000 cases per year starting in 2020. It also highlights that NPEs face higher patent invalidation rates compared to non-NPEs, indicating potential patent quality issues.
OMRON, a leading automation company, has selected IPfolio™, an intellectual property management software from Clarivate Plc (NYSE: CLVT), to transform their IP operations. The solution aims to maximize operational efficiency by leveraging IP data and analytical insights, enabling OMRON to make smarter decisions and plan strategically. With IPfolio, OMRON can better manage its IP assets, increase productivity, and streamline processes.
Clarivate reported first-quarter 2024 results with revenues of $621.2 million, a 1.3% decrease. The net loss attributable to ordinary shares was $93.8 million. Adjusted net income decreased by 20.9% to $103.5 million. The company reaffirmed its outlook for 2024.
Clarivate Plc (NYSE: CLVT) has introduced Epidemiology Intelligence™, a new solution that provides biopharma companies with epidemiology, incidence, and prevalence data, along with claims-based population insights, to enhance market sizing and patient population analysis. The tool aims to address limitations in traditional research methods, offering unique insights for accurate forecasting and identification of niche populations. The launch signifies Clarivate's commitment to delivering comprehensive solutions to the life sciences and healthcare industries.
Clarivate Plc (NYSE:CLVT) has launched the enhanced Cortellis CMC Intelligence solution with a post-approval variations module. This update allows pharmaceutical companies to streamline regulatory tracking and optimize life cycle management for small molecules and biologics. The module covers regulatory changes across 64 countries, reducing tracking time and increasing submission rates. Cortellis CMC Intelligence aims to simplify CMC regulatory dossier submissions, automate monitoring through alerts, and offer comprehensive lifecycle information for drugs and biologics.
Clarivate Plc declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares, payable on June 3, 2024. Each Preferred Share will convert into ordinary shares based on the VWAP of Clarivate's shares. The conversion rate depends on the VWAP value, with specific ratios based on price levels. Shareholders of record on May 15, 2024, will receive the dividend.
BioWorld by Clarivate explores the future of CAR T therapy in mainland China, focusing on the rapid pipeline growth, partnerships, clinical trials, and patient access challenges in cancer treatment. The report highlights the exponential growth of China's CAR T market, the blooming CAR T pipelines, and the difficulties in providing access to CAR T therapies due to high costs and reimbursement challenges.
Summary not available.
Summary not available.